Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine1nevirapine regimen

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2866-2870

  Allavena, C ^a,b   Bach Ngohou, K ^a   Billaud, E ^a,c   Secher S ^c   Dejoie, T ^a   Reliquet, V ^a   Fakhouri, F ^a,b   Raffi, F ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c IUFM des Pays de Loire   (France)

Author keywords

HIV infection; NGAL; Nucleoside analogues; Renal toxicity

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; EMTRICITABINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CLINICAL ARTICLE; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MALE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL;

HIV INFECTION; NGAL; NUCLEOSIDE ANALOGUES; RENAL TOXICITY;

ACUTE-PHASE PROTEINS; ADENINE; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; NEVIRAPINE; ORGANOPHOSPHONATES; PROTO-ONCOGENE PROTEINS;

EID: 84887556911     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt265     Document Type: Article

References (21)

1. Mocroft A, Kirk O,Gatell J et al. Chronic renal failureamongHIV-1-infected patients. AIDS 2007; 21: 1119-27.
2. Dauchy FA, Lawson-Ayayi S, de La Faille Ret al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011; 80: 302-9.
3. Valle R, Haragsim L. Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 2006; 13: 314-9.
4. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
5. Flandre P, Pugliese P, Cuzin L et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J AmSoc Nephrol 2011; 6: 1700-7.
6. Mocroft A, Kirk O,Reiss P et al. Estimated glomerular filtrationrate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-78.
7. Scherzer R, Estrella M, Li Y et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-75.
8. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010; 15: 419-28.
9. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease. Clin J AmSoc Nephrol 2009; 4: 337-44.
10. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 469-79.
11. Landro L, Damas JK, Flo TH et al. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol 2008; 152: 57-63.
12. Rodriguez-Novoa S, Labarga P, D'Avolio A et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064-6.
13. Nickolas TL, Forster CS, Sise M.E et al. NGAL(Lcn2)monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int 2012; 82: 718-22.
14. Kalayjian RC, Lau B, Mechekano RN et al. Risk factors for chronic kidney disease inalargecohort of HIV-1infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26: 1907-15.
15. BorregaardN, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006; 19: 211-5.
16. Sola-Del Valle DA, Mohan S, Cheng JT et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant 2011; 26: 2387-90.
17. Oboho I, Abraham A, Benning L et al. Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2012; doi:10.1097/ QAI.0b013e31828175c9.
18. Thrailkill KM, Moreau CS, Cockrell GE et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 2010; 37: 336-43.
19. Rasmussen TA, Jensen D, TolstrupMet al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 2012; 7: e32445.
20. Campbell LJ, Dew T, Salota R et al. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol 2012; 13: 85.
21. Delanaye P, Rozet E, Krzesinski JM et al. Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta 2011; 412: 390.